Pfizer begins testing use of pnuemococcal vaccine along with Covid-19 booster shot
The study will include 600 adults over 65 years who will be recruited from the late-stage study of the Pfizer-BioNTech Covid-19 vaccine, and will have received their second dose of the vaccine at least six months prior to entering the co-administration study, the company said
FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Pfizer logo in this illustration taken February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
Pfizer Inc said on Monday it has started immunizing the first patients in a new study looking at administering the company's 20-valent pneumococcal conjugate vaccine candidate following a booster dose of the Pfizer-BioNTech Covid-19 shot.
The study will include 600 adults over 65 years who will be recruited from the late-stage study of the Pfizer-BioNTech Covid-19 vaccine, and will have received their second dose of the vaccine at least six months prior to entering the co-administration study, the company said.
Keep updated, follow The Business Standard's Google news channel
